Journal of Peking University(Health Sciences) ›› 2017, Vol. 49 ›› Issue (5): 910-914. doi: 10.3969/j.issn.1671-167X.2017.05.030

• Article • Previous Articles     Next Articles

Changes of serum Krebs von den Lungen-6 levels in interstitial lung disease associated with dermatomyositis and secondary Sjögren’s syndrome: a case report

YU Jian-feng1, 2, *, JIN Yue-bo1, *, HE Jing1, AN Yuan1, LI Zhan-guo1   

  1. 1. Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing 100044, China;
    2. Department of Nephrology and Rheumatology, The Third People’s Hospital in Hubei Province, Wuhan 430000, China
  • Received:2015-12-01 Online:2017-10-18 Published:2017-10-18

Abstract: SUMMARY Interstitial lung diseases (ILDs) are a diverse group of pulmonary disorders characterized by various patterns of inflammation and fibrosis in the interstitium of the lung. The underlying pathogenesis of ILDs is complex and associated with multiple rheumatologic conditions, such as systemic sclerosis, rheumatoid arthritis, pollymyositis and dermatomyositis, Sjögren’s syndrome, and systemic lupus erythematosus. As the disease progresses, excessive pulmonary fibrosis impairs alveolar gas exchange and damages pulmonary function. The common methods to diagnose ILDs, such as clinical manifestations, pulmonary function test, and radiological examinations are not specific for ILDs and not able to diagnose ILDs at the early stage due to their low sensitivity. So, the easy way is important to diagnose ILDs. One important biomarker for ILDs is the high-molecular-weight glycoprotein, Krebs von den Lungen-6(KL-6). KL-6 encoded by the MUC1 gene is a mucin-like glycoprotein with high molecular weight and expressed predominantly on the cell surface of type Ⅱ alveolar epithelial cells, and is detectable in the serum of patients with ILDs. We here report a case of ILDs associated with dermatomyositis and secondary Sjögren’s syndrome. A 60-year-old woman was admitted to our hospital with the chief complaints of debilitation, dry mouth, dyspnea and astasia. ILDs associated with dermatomyositis and secondary Sjögren’s syndrome was diagnosed clinically when the following criteria were satisfied: (1) development of dyspnea within 2 months of presentation, (2) pulmonary dispersion dysfunction, (3) bilateral infiltrative shadows on chest high resolution computed tomography (HRCT). She was treated with prednisone 50 mg/d prior to admission, but the result of therapy was not good. In our hospital she was treated with intravenous methylprednisolone and cyclophosphamide and oral hydroxychloroquine sulfate. Subsequently, her serum KL-6 levels gradually decreased after treatment, pulmonary diffuse function improved, and the improvement in the clinical manifestation and HRCT findings were observed. Nevertheless, the combination treatment of glucocorticoid and cyclophosphamide had contributed to the favourable outcomes. In conclusion, detection of serum KL-6 levels in ILDs associated with connective tissue diseases may be be-neficial to making a definitive diagnosis, predicting the prognosis and monitoring the disease activity, which would be of great help in clinical practice. However, a well-designed clinical study with more patients and a longer follow-up period are required to arrive at a more conclusive judgment on the role of serum KL-6 in patients with ILDs.

Key words: Dermatomyositis, Sjögren’s syndrome, Interstitial lung disease, Serum Krebs von den Lungen-6

CLC Number: 

  • R593.2
[1] Kohno N, Awaya Y, Oyama T, et al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease[J]. Am Rev Respir Dis, 1993, 148(3): 637-642.
[2] Bandoh S, Fujita J, Ohtsuki Y, et al. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis[J]. Ann Rheum Dis, 2000, 59(4): 257-262.
[3] Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease[J]. Am J Respir Crit Care Med, 2001, 164(7): 1182-1185.
[4] Marie I, Hachulla E, Chérin P, et al. Interstitial lung disease in polymyositis and dermatomyositis[J]. Arthritis Rheum, 2002, 47(6): 614-622.
[5] Nukiwa T. The role of biomarkers in management of interstitial lung disease: implication of biomarkers derived from type Ⅱ pneumocytes[M]// Du Bois RM, Richeldi L, editors. The European respiratory monograph 46 interstitial lung disease[M]. Leeds: Maney Publishing, 2009: 47-66.
[6] Fathi M, Barbasso Helmers S, Lundberg IE. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis[J]. J Intern Med, 2012, 271(6): 589-597.
[7] Hu Y, Wang LS, Jin YP, et al. Serum Krebs von den Lungen-6 level as a diagnostic biomarker for interstitial lung disease in Chinese patients[J]. Clin Respir J, 2017, 11(3): 337-345.
[8] Ohshimo S, Ishikawa N, Horimasu Y, et al. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis[J]. Respir Med, 2014, 108(7): 1031-1039.
[9] Honda K, Okada F, Ando Y, et al. Comparison of pulmonary thin section CT findings and serum KL-6 levels in patients with sarcoi-dosis[J]. Br J Radiol, 2011, 84(999): 229-235.
[10] Kinoshita F, Hamano H, Harada H, et al. Role of KL-6 in eva-luating the disease severity of rheumatoid lung disease:comparison with HRCT[J].Respir Med, 2004, 98(11): 1131-1137.
[11] Chen F, Lu X, Shu X, et al. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study[J]. Intern Med J, 2015, 45(6): 641-647.
[12] Janssen R, Kruit A, Grutters JC, et al. The mucin-1 568 adenosine to guanine polymorphism influences serum Krebs von den Lungen-6 levels[J]. Am J Respir Cell Mol Biol, 2006, 34(4): 496-499.
[13] Ishikawa N, Hattori N, Yokoyama A, et al. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases[J]. Respir Investig, 2012, 50(1): 3-13.
[1] Zhanhong LAI,Jiachen LI,Zelin YUN,Yonggang ZHANG,Hao ZHANG,Xiaoyan XING,Miao SHAO,Yuebo JIN,Naidi WANG,Yimin LI,Yuhui LI,Zhanguo LI. A unicenter real-world study of the correlation factors for complete clinical response in idiopathic inflammatory myopathies [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 284-292.
[2] Qi WU,Yue-ming CAI,Juan HE,Wen-di HUANG,Qing-wen WANG. Correlation between dyslipidemia and rheumatoid arthritis associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 982-992.
[3] Wen-gen LI,Xiao-dong GU,Rui-qiang WENG,Su-dong LIU,Chao CHEN. Expression and clinical significance of plasma exosomal miR-34-5p and miR-142-3p in systemic sclerosis [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1022-1027.
[4] Xiao-yan XING,Jun-xiao ZHANG,Feng-yun-zhi ZHU,Yi-fan WANG,Xin-yao ZHOU,Yu-hui LI. Clinical analysis of 5 cases of dermatomyositis complicated with macrophage activation syndrome [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1214-1218.
[5] ZHANG Pu-li,YANG Hong-xia,ZHANG Li-ning,GE Yong-peng,PENG Qing-lin,WANG Guo-chun,LU Xin. Value of serum YKL-40 in the diagnosis of anti-MDA5-positive patients with dermatomyositis complicated with severe pulmonary injury [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1055-1060.
[6] ZHU Yi-ying,MIN Sai-nan,YU Guang-yan. Effect of topical injection of cyclosporine A on saliva secretion and inflammation in the submandibular gland of non-obese diabetic mice [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 750-757.
[7] XIA Fang-fang,LU Fu-ai,LV Hui-min,YANG Guo-an,LIU Yuan. Clinical characteristics and related factors of systemic lupus erythematosus with interstitial pneumonia [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 266-272.
[8] Yu-zhou GAN,Yu-hui LI,Li-hua ZHANG,Lin MA,Wen-wen HE,Yue-bo JIN,Yuan AN,Zhan-guo LI,Hua YE. Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1001-1008.
[9] Jing XU,Jing XU,He LI,Jie TANG,Jian-long SHU,Jing ZHANG,Lian-jie SHI,Sheng-guang LI. Dermatomyositis combined with IgA vasculitis: A case report [J]. Journal of Peking University(Health Sciences), 2019, 51(6): 1173-1177.
[10] Yi-ying YANG,Xiao-xia ZUO,Hong-lin ZHU,Si-jia LIU. Advances in epigenetic markers of dermatomyositis/polymyositis [J]. Journal of Peking University(Health Sciences), 2019, 51(2): 374-377.
[11] LIU Shuang, AN Yuan, JIA Yuan, LI Zhan-Guo. A case of clinical overlap syndrome of rheumatoid arthritis and amyopathic dermatomyositis with multiple pulmonary injuries [J]. Journal of Peking University(Health Sciences), 2014, 46(5): 805-808.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!